Richard Hedelius, DO
Pulmonary Disease · Atlanta, GANPI 1376703645
Payments from drug & device makers
Across 262 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- GSK$1K
- Boehringer Ingelheim$990
- Grifols USA, LLC$644
- Mylan Specialty L.p.$305
- AstraZeneca$288
- plus $2K from 21 others
What the payments were for
- Travel & lodging$1,84323%
- Food & beverage$6,18076%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 21 | $2,682 |
| GSK | 73 | $1,382 |
| Boehringer Ingelheim | 46 | $990 |
| Grifols USA, LLC | 26 | $644 |
| Mylan Specialty L.p. | 14 | $305 |
| AstraZeneca | 16 | $288 |
| Cook Medical LLC | 1 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $199 |
| Insmed, Inc. | 6 | $198 |
| Baxter Healthcare | 9 | $186 |
| Regeneron Healthcare Solutions, Inc. | 6 | $185 |
| Sanofi | 5 | $161 |
| Verona Pharma, Inc. | 6 | $122 |
| Viatris Specialty LLC | 5 | $113 |
| Body Vision Medical Inc. | 1 | $97 |
| Fisher & Paykel Healthcare Inc | 4 | $68 |
| CSL Behring | 2 | $40 |
| Pfizer | 2 | $38 |
| Novartis | 2 | $36 |
| AbbVie | 2 | $31 |
| Olympus America Inc. | 1 | $26 |
| Ambu Inc. | 1 | $23 |
| Acacia Pharma Inc | 1 | $22 |
| Pulmonx Corporation | 1 | $21 |
| Resmed Corp | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Breas Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$2,289
- Blue Rhino$261
- Arcpoint$125
- AREXVY$108
- NUCALA$104
How this compares
$8,159 in reported general payments places this provider in the 60th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $636,831 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 852 | $600,307 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $27,811 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $25,363 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $22,494 |
| EliquisApixaban | 19 | $16,096 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $15,751 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,614 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,244 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $7,323 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 186 | $5,725 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $3,593 |
| Esomeprazole Magnesium | 86 | $2,170 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,894 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $990 | $663,19694 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,382 | $656,407963 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $288 | $35,13461 claims |
| PfizerEliquis | $38 | $16,09619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Srihari VeeraraghavanAtlanta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Colin SwensonAtlanta$777K
- Paul BoyceAtlanta$406K
- Ishan MehtaAtlanta$198K
- Seth WalkerAtlanta$189K
- Annette EsperAtlanta$186K
- Avanthika WynnAtlanta$181K
- David BerkowitzAtlanta$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.